1. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study 
Laura L Hammitt, MD, Anthony O Etyang, ChB, Susan C Morpeth, FRACP, John Ojal, PhD, Alex Mutuku, MSc, Neema Mturi, MRCPCH, Jennifer C Moisi, PhD, Ifedayo M Adetifa, PhD, Angela Karani, BSc, Donald O Akech, BSc, Mark Otiende, MSc, Tahreni Bwanaali, MBA, Jackline Wafula, BSN, Christine Mataza, KRCHN, Edward Mumbo, BSc, Collins Tabu, MPH, Maria Deloria Knoll, PhD, Evasius Bauni, PhD, Prof Kevin Marsh, FMedSci, Prof Thomas N Williams, FMedSci, Tatu Kamau, MPH, Shahnaaz K Sharif, MD, Prof Orin S Levine, PhD, Prof J Anthony G Scott, FRCP 
The Lancet 
DOI: /S (18)
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

2. Figure 1 Proportion of children vaccinated with PCV10
(A) 0–11 months of age. (B) 12–23 months of age. (C) 24–59 months of age. (D) 5–9 years of age in the Kilifi Health and Demographic Surveillance System, 2011–16. PCV10=ten-valent pneumococcal conjugate vaccine.
The Lancet DOI: ( /S (18) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

3. Figure 2
Incidence of overall, vaccine-type, and non-vaccine-type invasive pneumococcal disease in the Kilifi Health and Demographic Surveillance System, 1999–2016
(A) In individuals aged <5 years. (B) 5–14 years. (C) ≥15 years. Vertical dashed line indicates pneumococcal conjugate vaccine introduction. IPD=invasive pneumococcal disease. VT=vaccine serotype.
The Lancet DOI: ( /S (18) )
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions